MONTREAL, May 16, 2024
/CNW/ - Pendopharm, a division of Pharmascience Canada
("Pendopharm"), is pleased to announce the renewal of its exclusive
distribution agreement with Anika Therapeutics Inc (NASDAQ: ANIK)
(Anika) for Cingal®, Monovisc® and
Orthovisc® through the end of 2030.
Since 2012, Pendopharm has partnered with Anika, a global joint
preservation company providing innovative & high-quality
products therapeutic solutions to healthcare professionals and
their patients.
"This partnership reinforces our shared commitment in restoring
active living for Canadian patients" says Jad Isber, Vice President, and General Manager
of Pendopharm. "We will continue to provide quality treatment
for patients suffering from musculoskeletal disorders."
"We are delighted at Anika to have agreed a long-term extension
to our strong partnership with Pendopharm in Canada," says Cheryl R. Blanchard, Ph.D., President, and CEO
of Anika Therapeutics. The continuation of this successful
relationship will ensure we continue to bring Cingal®,
our single injection, next generation, non-opioid treatment for OA
pain, along with our other leading OA Pain technologies, to
patients all over Canada for years
to come."
© 2024 Pendopharm, division of Pharmascience Inc. All rights
reserved.
ABOUT PENDOPHARM
Pendopharm, division of Pharmascience Inc., is a leading
Canadian specialty pharmaceutical company providing patients with
innovative medicines that address unmet medical needs. Its areas of
focus are gastroenterology, sports medicine & orthopedics,
neurology and cardiology. Pendopharm has extensive experience
and knowledge to successfully manage its growing product
portfolio.
Additional information: www.pendopharm.com
ABOUT PHARMASCIENCE INC.
Founded in 1983, Pharmascience Inc. is the largest
pharmaceutical employer in Quebec
with 1,500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service
privately owned pharmaceutical company with strong roots in
Canada and a growing global reach
with product distribution in over 50 countries. Ranked 52nd among
Canada's top 100 Research &
Development (R&D) investors in 2023, with 40-50 million dollars invested each year,
Pharmascience Inc. is among the largest drug manufacturers in
Canada.
ABOUT ANIKA
Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint
preservation company that creates and delivers meaningful
advancements in early intervention orthopedic care. Leveraging our
core expertise in hyaluronic acid and implant solutions, we partner
with clinicians to provide minimally invasive products that restore
active living for people around the world. Our focus is on high
opportunity spaces within orthopedics, including Osteoarthritis
Pain Management, Regenerative Solutions, Sports Medicine and
Arthrosurface Joint Solutions, and our products are efficiently
delivered in key sites of care, including ambulatory surgery
centers. Anika's global operations are headquartered outside of
Boston, Massachusetts. For
more information about Anika, please visit www.anika.com.
SOURCE Pendopharm